Gain-of-function mutations in KIT receptor in humans are associated with gastrointestinal stromal tumors, systemic mastocytosis and acute myelogenous leukemia. The intracellular signals that contribute to oncogenic KIT-induced myeloproliferative disease (MPD) are poorly understood. Here, we show that oncogenic KITD814V-induced MPD occurs in the absence of ligand stimulation. The intracellular tyrosine residues are important for KITD814V-induced MPD, albeit to varying degrees. Among the seven intracellular tyrosines examined, tyrosine 719 alone has a unique role in regulating KITD814V-induced proliferation and survival in vitro, and MPD in vivo. Importantly, the extent to which AKT, extracellular signal-regulated kinase and Stat5 signaling pathways are activated via the seven intracellular tyrosines in KITD814V impacts the latency of MPD and severity of the disease. Our results identify critical signaling molecules involved in regulating KITD814V-induced MPD, which might be useful for developing novel therapeutic targets for hematologic malignancies involving this mutation.
INTRODUCTION
The proto-oncogene KIT belongs to the receptor tyrosine kinase class III family, which includes the macrophage colony-stimulating factor receptor, the platelet-derived growth factor receptor, as well as the F1 cytokine receptor (FLT3). 1 The KIT receptor has a crucial role in cell proliferation, differentiation, survival and migration through activation of diverse signaling pathways. 2 Binding of its ligand, stem cell factor (SCF), induces KIT receptor dimerization and autophosphorylation on intracellular tyrosine residues leading to the recruitment and docking of src homology 2 (SH2) containing signaling molecules to the seven critical intracellular tyrosines. 3 Although the individual and combined importance of these tyrosines in normal KIT receptor signaling is beginning to emerge; the role of these tyrosines in oncogenic KITinduced myeloproliferative disease (MPD) is poorly understood. Furthermore, it is unclear whether these tyrosines have a unique, redundant or overlapping function in inducing MPD.
Activating mutations in KIT receptor have been shown to be involved in various human diseases including gastrointestinal stromal tumors, systemic mastocytosis and acute myelogenous leukemia. 4 --7 An activating KIT mutation within the tyrosine kinase domain, such as KITD814V in mice or KITD816V in humans, results in ligand-independent tyrosine kinase activity leading to constitutive autophosphorylation and activation of downstream signaling pathways. 8, 9 As a result, KITD814V-bearing cells demonstrate ligand-independent proliferation in vitro and MPD in vivo. 8 --12 However, the intracellular mechanisms that contribute to KITD814V-induced MPD are not known. In addition, primary hematopoietic stem and progenitors (HSC/Ps) bearing KITD814V show a further increase in proliferation in the presence of KIT ligand, SCF, relative to cells grown in the absence of SCF, 11 which suggests that endogenous ligand stimulation may contribute to oncogenic KIT-induced transformation in vivo. Therefore, it is still unclear whether ligand-independent growth observed in vitro via KITD814V is sufficient to induce MPD in vivo or whether presence of SCF is necessary to drive MPD.
Although KIT mutations within the juxtamembrane domain found in gastrointestinal stromal tumor are highly sensitive to inhibition by imatinib (that is, Gleevec), KIT mutations within tyrosine kinase domain involved in systemic mastocytosis and acute myelogenous leukemia, including KITD816V, are resistant to imatinib treatment. 13 --15 Currently, there are no therapies available for human diseases involving KITD816V mutation. Thus, it is important to identify signaling pathways that are involved in KITD814V-induced MPD to develop novel therapeutic targets for diseases involving this mutation. Utilizing biochemical and genetic approaches, we demonstrate that endogenous ligand (that is, SCF) binding is dispensable for KITD814V-induced MPD. Furthermore, the intracellular tyrosine residues are important for KITD814V-induced MPD, albeit to varying degrees. Among the seven intracellular tyrosines examined, tyrosine 719 alone has a unique role in regulating KITD814V-induced proliferation in vitro, and MPD in vivo. Importantly, tyrosine 719 is vital for the activation of phosphatidylinositol 3 kinase (PI3Kinase) and Stat5 downstream from KITD814V. Our results identify critical signaling molecules downstream from KITD814V, which might be useful for developing therapeutic targets for hematologic malignancies involving oncogenic forms of KIT.
Proliferation
Proliferation was assessed by conducting a thymidine incorporation assay as previously described 16 and described in detail in Supplementary Materials and Methods.
Western blotting
Western blot analysis was performed as previously reported. 16 Murine bone marrow (BM) transplantation A single intraperitoneal injection of 150 mg/kg of 5-fluorouracil was given to C57BL/6 mice. Low-density mononuclear cells were collected 72 h post 5-fluorouracil injection and transduced with retrovirus encoding the various KIT or CHR constructs as described previously. 16 In all, 1 Â 10 6 transduced cells and 1 Â 10 5 supporting fresh splenocytes from C57BL/6 mice were intravenously injected through tail vein into lethally irradiated (1100 cGY-split dose) recipient mice. Transplanted mice were monitored for MPD development and survival. Mice were harvested at moribund and BM, spleen, thymus and peripheral blood were harvested for flow cytometric analysis, and histology by hematoxylin and eosin staining.
Statistics
All graphical data were evaluated by paired Student's t-test and results were considered significantly different with P-value o0.05. All data are represented as mean values ± s.d. Survival probability of transplanted mice cohorts were compared using a Kaplan --Meier survival analysis in which statistical significance was determined as P-values o0.05 by log-rank test.
RESULTS

Construction of WT and mutant chimeric KIT receptors
Along with others, we have previously shown that KITD814V is sufficient to induce ligand-independent growth in vitro as well as MPD in vivo. 8 --11,17 It is, however, unclear whether KITD814V-induced ligand-independent growth observed in vitro is sufficient to cause MPD in vivo or whether presence of endogenous SCFinduced signals are essential for the development of MPD. To determine the contribution of ligand-independent growth in KITD814V-induced MPD in vivo, we generated a chimeric KIT receptor (CHR) in which the extracellular domain of KIT was replaced with the extracellular domain of human macrophage colony-stimulating factor receptor to inhibit the endogenous binding of murine SCF, but to maintain the transmembrane and intracellular domains of the murine KIT receptor 18, 19 (Supplementary Figure S1A ). This receptor allows studying the ligandindependent functions of KIT receptor in vivo as it maintains the intracellular functions of KIT receptor intact without endogenous binding of murine SCF or macrophage colony-stimulating factor (M-CSF), but is specifically activated by human M-CSF. 18, 19 The WT CHR is functionally and biochemically similar to the WT endogenous KIT receptor as previously reported. 18, 19 In addition, we constructed a mutant CHR (CHRD814V) that contains an oncogenic mutation of aspartic acid to valine at residue 814 of the WT CHR (Supplementary Figure S1A) . Parental and chimeric KIT receptors with or without D814V mutation were cloned into a bicistronic retroviral vector, MIEG3, which expresses enhanced green fluorescent protein through an internal ribosome entry site as previously described. 18, 19 Ligand-independent growth is sufficient to induce KITD814V-induced MPD in vivo We first verified whether our constructed chimeric KIT receptors function similar to their WT and KITD814V counterparts. We performed proliferation assay in 32D myeloid cells bearing parental or chimeric KIT receptors with or without D814V mutation by assessing thymidine incorporation. As expected, cells bearing KITD814V or CHRD814V showed similar levels of ligand-independent growth (Supplementary Figure S1B) . In contrast, cells bearing WT KIT or WT CHR showed minimal thymidine incorporation in the absence of growth factors (Supplementary Figure S1B) . In addition, cells bearing WT CHR showed increased growth in the presence of human M-CSF, but not murine M-CSF (Supplementary Figure S1C ). These findings demonstrate that CHRs (WT CHR and CHRD814V) function in a manner similar to their parental counterparts with respect to ligand-independent growth and specifically respond to human M-CSF, but not murine M-CSF. Therefore, these CHRs could be used to determine the impact of ligand-independent growth in KITD814V-induced MPD in vivo.
To determine the role of ligand-independent growth in KITD814V-induced MPD in vivo, we used a murine transplantation model that we have previously described. 17 Low-density mononuclear cells from 5-fluorouracil-treated C57BL/6 mice were transduced with WT CHR, WT KIT, KITD814V or CHRD814V, and sorted cells were transplanted into lethally irradiated recipient mice. Figure S2F) . Some mice transplanted with cells bearing CHRD814V also demonstrated erythroleukemia, B-cell and T-cell lymphomas in addition to MPD, similar to other published models of oncogene-induced MPD (data not shown). 20 Taken together, these results indicate that KITD814V mutation does not require a direct engagement with its ligand SCF to induce MPD in vivo.
Intracellular tyrosine residues in KITD814V are essential for ligandindependent growth in vitro We next focused our studies to determine the importance of intracellular tyrosine residues in KITD814V-induced ligand-independent growth. To address this, we constructed a CHRD814V mutant receptor (CHRD814V-F7) in which all the intracellular tyrosine residues were converted to phenylalanine by site directed mutagenesis as shown in Figure 1a . 32D cells were transduced with WT CHR, CHRD814V or CHRD814V-F7, sorted to homogeneity based on enhanced green fluorescent protein expression and used to perform proliferation assay. Consistent with our earlier result (Supplementary Figure S1B) , cells bearing CHRD814V, but not WT CHR, showed ligand-independent growth (Figure 1b) . However, conversion of all the seven intracellular tyrosine residues in CHRD814V to phenylalanine (CHRD814V-F7) resulted in loss of ligand-independent growth (Figure 1b) . These results suggest that intracellular tyrosine residues in KITD814V are essential for ligandindependent growth.
To identify which of the tyrosine residue has a critical role in KITD814V-induced ligand-independent growth in vitro and transformation in vivo, we generated seven different single tyrosine add-back mutants at residues 567, 569, 702, 719, 728, 745 and 934 in the KIT intracellular domain using CHRD814V-F7 as the template (Figure 2a ). These CHRD814V mutant receptors were designated CHRD814V-Y567, CHRD814V-Y569, CHRD814V-Y702, CHRD814V-Y719, CHRD814V-Y728, CHRD814V-Y745 and CHRD814V-Y934. 32D cells, which lack endogenous KIT receptor, were infected with these mutant CHRD814V receptors and sorted Figure S3A) . Among all the single tyrosine add-back CHRD814V receptors, CHRD814V-Y719 was the only receptor whose expression maintained survival at a level similar to that of CHRD814V receptor (Supplementary Figure S3A) . There was no significant difference in the cycling status of cells bearing various mutant CHRD814V receptors, including CHRD814V and CHRD814V-Y719, when grown in the absence of growth factors (Supplementary Figure S3B) . These results show that intracellular tyrosine residues in KITD814V receptor are essential for ligand-independent growth. Among these tyrosine residues, tyrosine at residue 719, which is the binding site for class I A PI3Kinase regulatory subunit p85a, is sufficient to rescue ligandindependent proliferation in vitro to CHRD814V levels.
Intracellular tyrosine residues in KITD814V contribute to MPD in vivo, albeit to varying extent To determine the physiologic role of the intracellular tyrosine residues in KITD814V-induced MPD in vivo, we transduced primary HSC/Ps from 5-fluorouracil-treated C57BL/6 mice with WT CHR, CHRD814V or CHRD814V with none or single tyrosine add-back mutants. Transduced cells showing similar transduction efficiencies were sorted to homogeneity and transplanted into lethally irradiated recipient mice. Mice were monitored for MPD development and survival. Although mice transplanted with cells bearing WT CHR showed no signs of disease and survived throughout the study, mice transplanted with cells bearing CHRD814V (red line) succumbed to death within 80 days of transplantation and developed a fatal MPD (Supplementary Figure S2A and Figure 3a) . In addition, mice transplanted with cells bearing CHRD814V-F7 (black line), which lack all the seven intracellular tyrosine residues, significantly delayed MPD development and prolonged overall survival (Figure 3a-1) . In the CHRD814V-F7 group, only 70% of the mice died within 180 days of transplantation and remaining 30% showed no signs of disease and appeared normal. These data suggest that the intracellular tyrosine residues in KITD814V are critical for efficient transformation in vivo.
Consistent with in vitro proliferation, among all the mice transplanted with cells bearing various CHRD814V mutant receptors, only recipient mice expressing CHRD814V-Y719 (blue line) showed similar MPD progression and survival as the CHRD814V-bearing mice (Figure 3a-5) . The median time of survival in these two groups was 60 days for CHRD814V vs 55 days for CHRD814V-Y719. In addition, recipient mice with cells bearing CHRD814V-Y567, CHRD814V-Y569, CHRD814V-Y728, CHRD814V-Y745 and CHRD814V-Y934 showed a significant delay in MPD development and survival compared with CHRD814V-bearing mice (median time of survival 105, 128, 95, 104 and 68 days, respectively, *Po0.05). Restoration of Y702 demonstrated a modest but nonsignificant delay in the disease onset compared with CHRD814V-bearing mice (median time of survival 76 days, P ¼ 0.077). Consistent with the survival data, histological analysis of BM, spleen, liver and lungs from the recipient mice transplanted with cells bearing various single tyrosine add-back CHRD814V mutants showed variable degree of infiltration of immature cells relative to CHRD814V-bearing mice or CHRD814V-Y719-bearing mice (Supplementary Figure S2E and Figure 3b ). These results suggest that among the seven intracellular tyrosine residues in KITD814V, tyrosine residue at 719 is sufficient to induce fully penetrant MPD in vivo. Other tyrosine residues at 567, 569, 702, 719, 728, 745 and 934 do contribute to KITD814V-induced MPD, however, to a lesser extent, resulting in delayed disease onset and reduced severity.
Differential activation of PI3Kinase, Stat5, and ERK mitogenactivated protein kinase in cells bearing various single tyrosine add-back CHRD814V mutant receptors To assess the biochemical basis for the differential role of single tyrosine add-back CHRD814V mutants in ligand-independent growth and MPD, activation of AKT, Stat5 and extracellular signal-regulated kinase (ERK), which are known to be critical for KITD814V-induced MPD, was analyzed. 11, 17, 21, 22 As seen in Figure 4a PI3Kinase and Stat5 inhibitors suppress KITD814V-induced ligand-independent growth As cells bearing KITD814V show constitutive activation of AKT, Stat5 and ERK, we examined whether inhibition of PI3Kinase, Stat5 or ERK activation would suppress KITD814V-induced ligandindependent proliferation. We treated cells bearing WT CHR or CHRD814V with the PI3Kinase inhibitor LY294002, Stat5 inhibitor or MAP kinase kinase (MEK) inhibitor PD0325901, and assayed proliferation by thymidine incorporation. As seen in Figure 4c , LY294002 treatment completely suppressed the constitutive growth of cells bearing CHRD814V. In contrast, Stat5 inhibitor treatment showed only a partial but significant repression in the constitutive growth of cells bearing CHRD814V. In addition, MEK inhibitor treatment showed no significant effect on the constitutive growth of cells bearing CHRD814V. These results suggest that activation of PI3Kinase and Stat5 has an essential role in KITD814V-induced ligand-independent growth. As Stat5 inhibitor only partially suppressed the constitutive growth of cells bearing CHRD814V, PI3Kinase may also regulate the activation of other signaling molecules in addition to Stat5 in cells bearing KITD814V.
PI3Kinase pathway is essential for KITD814V-induced ligandindependent proliferation via AKT and mTOR signaling To further determine the signaling molecules downstream of PI3Kinase that might contribute to the growth of KITD814V-bearing cells, we analyzed the involvement of AKT and mammalian target of rapamycin (mTOR). For this, we starved the cells bearing KITD814V in serum-and cytokine-free medium for 6 h and performed proliferation assays in the presence of indicated amounts of specific PI3Kinase inhibitor (GDC-0941), AKT inhibitor (AKT inhibitor VIII) or mTOR inhibitor (AZD8055) by thymidine incorporation. As seen in Figure 5a , KITD814V-induced ligand-independent proliferation is significantly suppressed in the presence of the specific inhibitors of PI3Kinase, mTOR and AKT, which suggests that PI3Kinase pathway is essential to KITD814V-induced ligand-independent proliferation via AKT and mTOR signaling. In contrast, although the MEK inhibitor (PD0325901) did not significantly repress KITD814V-induced proliferation even at high doses (Figure 4c) , a significant further suppression in ligandindependent proliferation in KITD814V-bearing cells in the presence of PI3Kinase inhibitor (GDC-0941) and MEK inhibitor (PD0325901) was observed (Figure 5b ). These results suggest that while MEK/ERK pathway alone is not critical; it can cooperate with the PI3Kinase pathway to regulate KITD814V-induced ligandindependent proliferation.
DISCUSSION
Our studies demonstrate that the direct binding of the ligand SCF to KITD814V receptor is not necessary to induce MPD and intracellular tyrosines are critical to this process. Mice bearing either the parental KITD814V receptor or the chimeric CHRD814V receptor (lacking the ability to be activated via its ligand SCF) show similar potency at inducing MPD with similar median survival. Furthermore, no significant difference in disease manifestation was observed between the two transplanted groups. Importantly, intracellular tyrosines show a critical role in CHRD814V-induced MPD and survival. Loss of seven critical tyrosine residues in CHRD814V, which are known to activate phospholipase C-g (728), 23, 24 PI3Kinase (p85a; 719), 25 Src family kinases (567 and 569), 26 --28 Grb2 (702),
29
Grb7 (934) 29 and Ras GTPase activating protein (745) profoundly impaired disease onset and prolonged the survival of transplanted mice. Only 70% mice that were transplanted with cells bearing CHRD814V-F7 succumb to death with very long latency, while 30% mice were free of disease and survived for the remaining duration of the study. Using transduced primary HSC/Ps, we have previously demonstrated that KITD814V not only induces ligand-independent growth or responds to SCF, but also synergizes with interleukin-3 and M-CSF receptors to further enhance the growth of these cells in vitro. This suggests that KITD814V-induced ligand-independent growth and its ability to cooperate with other cytokines might also contribute to activating KIT-induced MPD. 11 Furthermore, KIT has also been shown to cooperate with granulocyte M-CSF in a kinase-independent manner 30 and to synergize with granulocyte colony-stimulating factor to induce proliferation. 31 Therefore, it is conceivable that CHRD814V-F7 is not sufficient to induce robust proliferation without growth factor in vitro, but may cooperate with additional cytokine receptors, such as interleukin-3, M-CSF and/or granulocyte colony-stimulating factor receptors to induce MPD in the 70% transplanted animals in a significantly delayed and milder manner.
In an effort to assess the role of individual tyrosine-mediated signals in KITD814V-induced MPD, we employed a unique approach. Although single point mutations in important tyrosine residues have been shown to affect KIT function, 32, 33 we felt that the approach of interfering with the binding of one or two SH2-binding proteins to CHRD814V, when all other SH2 proteins still retain the ability to bind may not allow for complete assessment of the importance of signals emanating from a single pathway, because it is possible that the remaining SH2 consisting proteins may compensate for the loss of a single binding site. We therefore employed a strategy where we could assess the role of an individual tyrosine-induced pathway in KITD814V-induced MPD. Using a version of the receptor that lacked all seven tyrosines (that is, CHRD814V-F7) as the template, we restored each of the SH2-binding sites from phenylalanine to tyrosine and tested their ability to induce growth in vitro and MPD in vivo, along with their potential to activate downstream signaling molecules known to be involved in KITD814V-induced MPD, including AKT, ERK and Stat5. We show a unique role for tyrosine 719 in regulating KITD814V-induced MPD. We show that restoring this site alone in the CHRD814V-F7 receptor is sufficient to completely rescue ligand-independent growth in vitro, MPD in vivo and activation of AKT, ERK and STAT5, similar to the CHRD814V receptor. Importantly, while the remaining add-back mutant receptors showed minimal rescue in ligand-independent growth in vitro; in vivo mice bearing these receptors demonstrated delayed MPD onset and prolonged latency compared with CHRD814V or CHRD814V-Y719 receptor-bearing mice. These results suggest that although ligand-independent growth is sufficient for KITD814V-induced MPD in vivo, presence of SCF and other cytokines might further regulate the MPD phenotype.
The variable onset of MPD and latency in mice transplanted with cells bearing various add-back mutant receptors was associated with differential rescue in the activation of AKT, ERK and STAT5. In general, add-back CHRD814V mutants that lacked the ability to rescue the activation of AKT, ERK and STAT5, such as CHRD814V-F7 receptor-bearing mice, demonstrated prolonged latency, while receptors demonstrating rescue in the activation of AKT and ERK, such as the CHRD814V-Y702 receptor-bearing mice, resulted in MPD, albeit at a slower rate. In contrast, receptors that robustly activated all three signaling molecules (ERK, AKT and Stat5) such as the CHRD814V-Y719 and the CHRD814V receptor, showed the shortest disease latency. Thus, KITD814V-induced MPD in vivo is largely dependent on the level of activation of AKT, ERK and STAT5, which to a large extent is regulated by signals emanating from tyrosine 719, suggesting that signals emanating from tyrosine 719 have a dominant role in regulating MPD, while the remaining tyrosine initiated signals contribute to MPD, albeit to a lesser extent. Thus, the impairment in the activation of essential signaling pathways is likely to contribute to a significant delay in the onset of MPD in mice bearing remaining add-back mutants of KITD814V.
Although recent studies have suggested that persistent activation of PI3Kinase and Stat5 is frequently observed in hematologic malignancies as well as in solid tumors, 34, 35 how exactly PI3Kinase contributes to KITD814V-induced MPD and/or Stat5 activation is unclear. We show that tyrosine 719 in KITD814V (binding site for p85a) contributes to the activation Stat5 . In cells expressing CHRD814V-F7, no binding of p85a is observed and Figure 5 . PI3Kinase pathway is essential for KITD814V-induced ligand-independent proliferation via AKT and mTOR signaling. (a) 32D cells bearing KITD814V receptor were starved in serum-and growth factor-free media for 6 h and subjected to proliferation assay in the absence of growth factors by thymidine incorporation. The proliferation assay was performed in the presence of individual inhibitors including PI3K inhibitor (GDC-0941), AKT inhibitor (AKT inhibitor VIII) or mTOR inhibitor (AZD8055) at indicated concentrations. Bars denote the mean thymidine incorporation (c.p.m. ± s.d.) from one of two independent experiments performed in quadruplicate. *Po0.05. (b) 32D cells bearing KITD814V receptor were starved in serum-and growth factor-free media for 6 h and subjected to proliferation assay in the absence of growth factors by thymidine incorporation. The proliferation assay was performed in the presence of PI3Kinase inhibitor (GDC-0941) and MEK inhibitor (PD0325901) individually or in a combination at indicated concentration. Bars denote the mean thymidine incorporation (c.p.m.±s.d.) from one of two independent experiments performed in quadruplicate. *Po0.05.
consistently no constitutive activation of Stat5 is observed (data not shown). Furthermore, deficiency of p85a in HSC/Ps expressing KITD814V results in complete inhibition of Stat5 activation. Importantly, restoring 719 from phenylalanine to tyrosine in CHRD814V-F7 completely rescues Stat5 activation. Thus, binding of p85a to tyrosine 719 in KITD814V is critical for Stat5 activation. These results suggest that PI3Kinase-mediated signaling is essential for constitutive activation of Stat5 in KITD814V-bearing cells. Although treatment of cells bearing KITD814V with the PI3Kinase, AKT and mTOR inhibitors profoundly suppressed the ligand-independent growth in vitro, treatment with Stat5 inhibitor only partially repressed the constitutive growth. These results, while consistent with our biochemical findings, suggest that in addition to Stat5, PI3Kinase might cooperate with other signaling molecules including the ERK pathway downstream from KITD814V to induce MPD. Taken together, our studies determine the contribution of SCF to KITD814V-induced MPD in vivo, and also identify critical tyrosine residues and signaling pathways involved in KITD814V-induced MPD.
